IL-6 Inhibition in Non-Infectious Uveitis

IL-6 — More Than Just an Inflammatory Cytokine

Discovered in the 1980s, IL-6 initially went by several different names because different laboratories discovered its different biological effects independently.

One molecule, many roles: IL-6 influences inflammation, immunity, hematopoiesis, metabolism, angiogenesis, and tissue repair.
A master acute-phase signal: IL-6 stimulates the liver to produce CRP, serum amyloid A, and fibrinogen.
A T-cell switch: Together with other cytokine signals, IL-6 can promote Th17 differentiation and influence the Th17–Treg balance.
Context matters: IL-6 signaling can contribute to host defense and tissue repair, but persistent or dysregulated signaling can drive chronic inflammation and autoimmunity.
The eye is not just a bystander: retinal and ocular cells can produce IL-6, and increased intraocular IL-6 has been described in several inflammatory retinal conditions.
Beyond inflammation: IL-6 is linked with VEGF expression, vascular permeability, angiogenesis, and fibrosis—making it particularly relevant to retinal disease.

How IL-6 causes uveitic macular oedema

Immune shift: IL-6 pushes naïve T cells towards Th17 cells and away from regulatory T cells, so inflammation keeps going (2).
VEGF induction: IL-6 raises VEGF, which makes vessels leak (2).
Barrier breakdown: IL-6 disrupts ZO-1 tight junctions in RPE cells, and IL-6R blockade reverses this in vitro. This points to the outer blood–retinal barrier (3).
Made inside the eye: aqueous IL-6 is high while serum IL-6 is normal (4), and levels are higher in active than in quiet uveitis (5).

Mechanism of Action:

IL-6 is a message produced by several cells in the eye, including macrophages, T-cells, RPE cells, and Müller cells. Once released, IL-6 travels to nearby cells and delivers an inflammatory signal. The sequence is like this: Macrophages / T-cells / RPE / Müller cells → IL-6 → IL-6R → gp130 → JAK → STAT3 → Nucleus

IL-6 is produced and released by macrophages, T-cells, RPE cells, Müller cells, and other cells.
IL-6 binds to IL-6R — its specific receptor, like a key fitting into a lock.
gp130 joins the complex and carries the message across the cell membrane.
JAK is activated inside the cell.
JAK switches on STAT3 by phosphorylation.
Activated STAT3 enters the nucleus and switches particular genes on or off.
The result is a change in cellular behaviour, including inflammation, immune activity, and cell survival.

So, to sumarise : Cells make IL-6 → IL-6 finds its receptor → gp130 passes the message inside → JAK activates STAT3 → STAT3 tells the nucleus which genes to switch on.

How the Drugs Block IL-6

Two strategies exist. Tocilizumab and sarilumab block the receptor and are given systemically. Vamikibart blocks IL-6 itself and is injected into the vitreous (6).

Receptor blockers versus ligand blocker

	Tocilizumab / sarilumab (systemic)	Vamikibart (intravitreal)
Target	IL-6 receptor, membrane-bound and soluble	IL-6 itself (the ligand)
Signalling blocked	Cis- and trans-signalling, throughout the body	Cis- and trans-signalling, within the eye
Antibody class	IgG1	IgG2, engineered for intravitreal use*
Persistence	Serum half-life about 21 days	Barely detectable in blood; ocular half-life about 7.5 days*

*Sponsor data presented at ARVO 2023; not yet peer-reviewed.

Two practical points on receptor blockers: tocilizumab suppresses CRP and fever, so an infection can hide behind a normal CRP. Serum IL-6 also rises on treatment because the blocked receptor can no longer clear it; this is expected and is not treatment failure.

The Evidence Trail: A Timeline

From discovery to phase 3

Year	Milestone
1986	IL-6 cloned by Kishimoto's group, first named B-cell stimulatory factor 2 (7)
1990	Raised aqueous IL-6 first reported in uveitis (4)
2005–2010	Tocilizumab licensed for systemic disease: Castleman disease in Japan, then rheumatoid arthritis (FDA 2010)
2006	Aqueous IL-6 linked to uveitis activity (5)
2013	First series: systemic tocilizumab dries refractory uveitic CME (8)
2014	Benefit holds at 12–18 months; CME relapses when the drug is stopped (9)
2016	Tocilizumab series in JIA uveitis and in refractory UME (10,11)
2017	STOP-Uveitis: first randomised trial of tocilizumab in non-infectious uveitis (12)
2017	Intravitreal anti-IL-6 attenuates mouse uveitis: first proof that local blockade works (13)
2018	Tocilizumab in Behçet uveitis after interferon and anti-TNF failure (14); 24-month UME outcomes (15)
2019	SATURN phase 2 (sarilumab) (16); 25-patient multicentre tocilizumab series (17); IL-6 breaks the RPE barrier in vitro (3)
2019–2023	DOVETAIL phase 1 of intravitreal vamikibart runs at 18 US sites (6)
2020	APTITUDE: tocilizumab in anti-TNF-refractory JIA uveitis (18); paediatric intermediate and panuveitis series (19)
2022	French Uveitis Network: tocilizumab versus anti-TNF in 204 patients (20)
2023	Review of IL-6 inhibition in UME (2); MEERKAT and SANDCAT phase 3 trials begin
2024	Intravitreal anti-IL-6 preserves visual function in mice (21)
2025–2026	MEERKAT and SANDCAT results presented (AAO 2025, ARVO 2026)
2026	DOVETAIL published (6)

Licensing dates are regulatory events and are not indexed in PubMed.

Proof of Concept: Systemic IL-6 Blockade in 12 Studies

Systemic tocilizumab and sarilumab have been tested across the full range of non-infectious uveitis. The table below summarises the 12 key studies in refractory UME (2).

Table. Refractory uveitis-related CME treated with systemic IL-6 inhibitors (adapted from Yang et al.)

Study	Drug (route)	Design	n	Uveitis type	F/U (mo)	Primary outcome	Primary efficacy	ME improved	Definition of improvement
Adán 2013 (8)	TCZ (IV)	CS	5	BCR 3, JIA 1, idiopathic panuveitis 1	8	CFT	100%	100% (5/5)	CFT <350
Mesquida 2014 (9)	TCZ (IV)	CS	7	BCR 3, JIA 3, idiopathic panuveitis 1	15	CFT	100%	71% (5/7)	CFT <350
Tappeiner 2016 (10)	TCZ (IV)	CS	5§	JIA	12	IOI	100%	100% (5/5)	N/A
Deuter 2016 (11)	TCZ (IV)	CS	5	JIA 2, AS 1, RA 2	14	CFT	75%	100% (5/5)	≥25% CFT reduction
Sepah 2017 (12)	TCZ (IV)	RCT	37	Idiopathic 28, sarcoid 2, VKH 2, BCR 2, PIC 1, BD 1, TINU 1	6	IOI	44%	100% (15/15)	N/A
Eser Ozturk 2018 (14)	TCZ (IV)‡	CS	5	BD	10	CFT	100%	80% (4/5)	N/A
Mesquida 2018 (15)	TCZ (IV)	CS	12	JIA 6, BCR 2, idiopathic panuveitis 2, SO 1, AS 1	24	CFT	100%	83% (10/12)	CFT <350, cysts resolved
Heissigerová 2018 (16)	SAR (SC)	RCT	58	Intermediate 12, posterior 14, panuveitis 29	4	RSU	46%	100% (58/58)†	≥20% CFT reduction
Vegas-Revenga 2019 (17)	TCZ (IV)	CS	25	JIA 9, BD 7, BCR 4, idiopathic panuveitis 4, sarcoid 1	12	CFT	100%	100% (25/25)	CFT <300, cysts resolved
Ramanan 2020 (18)	TCZ (SC)	SAT	21	JIA (refractory to anti-TNF and MTX)	9	IOI	34%	75% (3/4)	N/A
Wennink 2020 (19)	TCZ (IV)	CS	7	Idiopathic 5, panuveitis 2	18	CFT	100%	100% (7/7)	N/A
Leclercq 2021 (20)	TCZ (IV/SC)	CS	204¶	Idiopathic 97, BD 35, BCR 23, sarcoid 15, JIA 12, VKH 8, SpA 5, other 9	6	Composite (CFT <300 µm, RSU)	36%	56% (31/55)	CFT <300, cysts resolved

Rows are in chronological order; years follow the source table and may differ from the final print year. ‡Tocilizumab, confirmed from the original paper. †As given in the source table; SATURN reported oedema outcomes mainly for eyes with CST ≥300 µm at baseline. §Patients with macular oedema at baseline (17 treated in total). ¶Whole cohort, including 149 on anti-TNF agents; 55 received tocilizumab. AS, ankylosing spondylitis; BCR, birdshot chorioretinopathy; BD, Behçet disease; CFT, central foveal thickness; CS, case series; F/U, follow-up; IOI, intraocular inflammation; IV, intravenous; JIA, juvenile idiopathic arthritis; ME, macular oedema; MTX, methotrexate; PIC, punctate inner choroidopathy; RA, rheumatoid arthritis; RCT, randomised controlled trial; RSU, reduced steroid use; SAR, sarilumab; SAT, single-arm trial; SC, subcutaneous; SO, sympathetic ophthalmia; SpA, spondyloarthritis; TCZ, tocilizumab; TINU, tubulointerstitial nephritis and uveitis; VKH, Vogt–Koyanagi–Harada disease.

What this table tells us

Consistent benefit: oedema improved in 56–100% of eyes across about 400 patients. Broad reach: birdshot, JIA, Behçet, VKH, sarcoidosis and idiopathic disease all responded. Best head-to-head data: in 204 French patients, tocilizumab gave complete UME response more often than anti-TNF agents (odds ratio 2.10) (20). Weak design overall: only 2 of 12 are randomised trials, most series have 5–12 patients, and 'improvement' is defined differently in each. The catch: whole-body exposure brings neutropenia, raised lipids and liver enzymes, infection and bowel perforation. That is hard to justify when only the macula is involved.

Systemic versus Local IL-6 Blockade

Intravitreal anti-IL-6 antibody reduced clinical, angiographic and histological inflammation in mouse uveitis (13) and preserved visual function (21). This opened the door to treating the macula alone.

Table . Pros and cons of each route

	Systemic (IV/SC tocilizumab, SC sarilumab)	Local (intravitreal vamikibart)
Pros	Treats both eyes and the systemic disease (JIA, RA, Behçet). Controls vitritis and posterior uveitis as well as oedema. Largest evidence base (Table 4). Works after anti-TNF failure.	High drug level where the cytokine is made. Minimal systemic exposure: no neutropenia, lipid or liver signal expected. No steroid cataract or IOP rise. Suits eyes that cannot take another implant.
Cons	Neutropenia, raised lipids and liver enzymes, serious infection, bowel perforation. Needs blood monitoring; CRP masks infection. Drug at the retina limited by the blood–retinal barrier. Cost; largely off-label in uveitis.	Repeated injections with their own risks (subconjunctival haemorrhage, IOP spikes, endophthalmitis). Treats the macula, not vitritis, choroiditis or systemic disease. Short follow-up; not yet approved.
Best candidate	Bilateral or systemic disease; anti-TNF failure; JIA	Wet macula with otherwise quiet uveitis; steroid responder; glaucoma or post-filtering eye; young phakic patient

What the Local Trials Show

The phase 1 DOVETAIL trial gave 37 adults with UME (CST ≥325 µm) intravitreal vamikibart 0.25, 1 or 2.5 mg at day 1, week 4 and week 8. At week 12, vision improved by 9.9 letters (about two lines) and CST fell by 165 µm, with benefit at every dose. There was one treatment-related event (transient blurring) and no retinal vasculitis, occlusive or non-occlusive (6).

The twin phase 3 trials, MEERKAT and SANDCAT, compared 0.25 mg and 1 mg with sham, given monthly to week 16. So far the results are conference data only. MEERKAT met its primary endpoint (≥15-letter gain); SANDCAT did not. Yet both dried the macula equally: CST fell by about 200 µm, and about three in five eyes became dry versus one in six with sham.

Table . Local IL-6 blockade: trials at a glance

Trial	Design	Key result	Safety signal
DOVETAIL (phase 1) (6)	Open-label; 37 eyes; 3 doses	+9.9 letters; CST −165 µm at week 12	No retinal vasculitis
MEERKAT (phase 3)*	Sham-controlled; n = 245	Primary endpoint met; ~60% dry	No occlusive vasculitis reported
SANDCAT (phase 3)*	Sham-controlled; n = 256	Primary endpoint missed; similar drying	No occlusive vasculitis reported

*Conference data (AAO 2025, ARVO 2026; NCT05642312, NCT05642325); peer-reviewed publication awaited.

Reading the Evidence Honestly

Short follow-up: phase 3 data run only to 16 weeks; durability and dosing interval are unknown.
Inconsistent primary endpoint: MEERKAT succeeded and SANDCAT did not.
No steroid comparator: there is no comparison with a dexamethasone implant or periocular triamcinolone.
Oedema, not uveitis: the trials measure the macula, not vitritis, choroiditis or systemic disease.
Who benefits most? Results by uveitis subtype are not yet available.
Access: the drug is unapproved, and its cost in India is unknown.

References

Ghasemi H. Roles of IL-6 in ocular inflammation: a review. Ocul Immunol Inflamm. 2018;26(1):37-50. PMID: 28146368.
Yang JY, Goldberg D, Sobrin L. Interleukin-6 and macular edema: a review of outcomes with inhibition. Int J Mol Sci. 2023;24(5):4676. PMID: 36902105.
Mesquida M, Drawnel F, Lait PJ, et al. Modelling macular edema: the effect of IL-6 and IL-6R blockade on human blood-retinal barrier integrity in vitro. Transl Vis Sci Technol. 2019;8(5):32. PMID: 31667008.
Murray PI, Hoekzema R, van Haren MA, de Hon FD, Kijlstra A. Aqueous humor interleukin-6 levels in uveitis. Invest Ophthalmol Vis Sci. 1990;31(5):917-20. PMID: 2335453.
van Kooij B, Rothova A, Rijkers GT, de Groot-Mijnes JD. Distinct cytokine and chemokine profiles in the aqueous of patients with uveitis and cystoid macular edema. Am J Ophthalmol. 2006;142(1):192-4. PMID: 16815285.
Sharma S, Lin P, Hu A, et al. Interleukin 6 inhibition with vamikibart for uveitic macular edema: the phase 1 DOVETAIL nonrandomized clinical trial. JAMA Ophthalmol. 2026;144(5):442-451. PMID: 41954903.
Hirano T, Yasukawa K, Harada H, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature. 1986;324(6092):73-6. PMID: 3491322.
Adán A, Mesquida M, Llorenç V, et al. Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol. 2013;251(11):2627-32. PMID: 23893042.
Mesquida M, Molins B, Llorenç V, Sainz de la Maza M, Adán A. Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema. Ophthalmology. 2014;121(12):2380-6. PMID: 25204610.
Tappeiner C, Mesquida M, Adán A, et al. Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2016;43(12):2183-2188. PMID: 27633821.
Deuter CME, Zierhut M, Igney-Oertel A, et al. Tocilizumab in uveitic macular edema refractory to previous immunomodulatory treatment. Ocul Immunol Inflamm. 2017;25(2):215-220. PMID: 26731514.
Sepah YJ, Sadiq MA, Chu DS, et al. Primary (month-6) outcomes of the STOP-Uveitis study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with noninfectious uveitis. Am J Ophthalmol. 2017;183:71-80. PMID: 28887113.
Tode J, Richert E, Koinzer S, et al. Intravitreal injection of anti-interleukin (IL)-6 antibody attenuates experimental autoimmune uveitis in mice. Cytokine. 2017;96:8-15. PMID: 28267649.
Eser Ozturk H, Oray M, Tugal-Tutkun I. Tocilizumab for the treatment of Behçet uveitis that failed interferon alpha and anti-tumor necrosis factor-alpha therapy. Ocul Immunol Inflamm. 2018;26(7):1005-1014. PMID: 29020500.
Mesquida M, Molins B, Llorenç V, et al. Twenty-four month follow-up of tocilizumab therapy for refractory uveitis-related macular edema. Retina. 2018;38(7):1361-1370. PMID: 28520640.
Heissigerová J, Callanan D, de Smet MD, et al. Efficacy and safety of sarilumab for the treatment of posterior segment noninfectious uveitis (SARIL-NIU): the phase 2 SATURN study. Ophthalmology. 2019;126(3):428-437. PMID: 30316888.
Vegas-Revenga N, Calvo-Río V, Mesquida M, et al. Anti-IL6-receptor tocilizumab in refractory and noninfectious uveitic cystoid macular edema: multicenter study of 25 patients. Am J Ophthalmol. 2019;200:85-94. PMID: 30660771.
Ramanan AV, Dick AD, Guly C, et al. Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial. Lancet Rheumatol. 2020;2(3):e135-e141. PMID: 32280950.
Wennink RAW, Ayuso VK, de Vries LA, et al. Tocilizumab as an effective treatment option in children with refractory intermediate and panuveitis. Ocul Immunol Inflamm. 2021;29(1):21-25. PMID: 32058831.
Leclercq M, Andrillon A, Maalouf G, et al. Anti-tumor necrosis factor α versus tocilizumab in the treatment of refractory uveitic macular edema: a multicenter study from the French Uveitis Network. Ophthalmology. 2022;129(5):520-529. PMID: 34793830.
Hösel K, Chasan B, Tode J, Rose-John S, Roider JB, Ehlken C. Effect of intravitreal injection of anti-interleukin (IL)-6 antibody in experimental autoimmune uveitis in mice. J Ophthalmic Inflamm Infect. 2024;14(1):57. PMID: 39497001.
Carbonell D, Mahajan S, Chee SP, et al. Consensus recommendations for the diagnosis of vitreoretinal lymphoma. Ocul Immunol Inflamm. 2021;29(3):507-520. PMID: 34009095.

MEERKAT and SANDCAT phase 3 results are from conference presentations and are not yet indexed in PubMed; licensing dates in Table 3 are regulatory events. Neither carries a reference number.